Navigation Links
Nastech Appoints MDRNA, Inc. Directors Strategic Advisory Board
Date:2/5/2008

of Sterling Winthrop including marketing, strategic planning and general management, being appointed President of the U.S. Pharmaceutical business in 1993. Mr. Peters is a former Trustee and founding member of the Health Care Institute of New Jersey from 1996 to 2006; a former board member of the Pharmaceutical Research and Manufacturers of America from 1995 to 2005 and a former board member of the National Pharmaceutical Council from 1990 to 1993. Mr. Peters also served on the board of Diatide Inc. from 1994 to 1997. Mr. Peters holds a bachelors degree from Western Illinois University.

Steven C. Quay, M.D., Ph.D., has been employed by Nastech since August 2000 and currently serves as the Chairman of the Board and CEO. In 1999, Dr. Quay founded and was Chairman, President and CEO of Atossa Healthcare, Inc., which focused on the development of a proprietary platform of diagnostics and treatments related to breast cancer risk assessment and therapeutics and other healthcare products for women. Nastech acquired Atossa in August 2000. In 1991, Dr. Quay founded Sonus Pharmaceuticals, Inc., a company engaged in the research and development of drug delivery systems and oxygen delivery products based on emulsion and surfactant technology, where he served as CEO, President and a director until June 1999. In 1984, Dr. Quay founded Salutar, Inc. to develop contrast agents for magnetic resonance imaging. Two pharmaceuticals, OmniScan(R) and TeslaScan(R), were invented by Dr. Quay at Salutar and have been used in over 35 million patients since the drugs received regulatory approval. Dr. Quay has authored more than 100 papers in diagnostic imaging, oncology, RNA interference and biochemistry and holds 65 U.S. patents. Dr. Quay graduated from the University of Michigan Medical School, where he received an M.A. and a Ph.D. in biological chemistry in 1974 and 1975, respectively, and an M.D. in 1977. Dr. Quay completed his post-graduate work in the chemistry department of Mass
'/>"/>

SOURCE Nastech Pharmaceutical Company Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine news :

1. Nastech to Establish Subsidiary, MDRNA, Inc., as an Independent Company to Focus on the Development of RNA-Based Therapeutics
2. Nastech Pharmaceutical Company Initiates Plan for Corporate Restructuring and Will Concentrate on Phase 2 Clinical Programs
3. Nastech Pharmaceutical Company Announces the Jeffrey Wenig Memorial Award for Outstanding Achievement in Drug Delivery
4. Nastech Pharmaceutical Company Announces Promotion of Rick Costantino, Ph.D., to Chief Scientific Officer of Delivery
5. Milestone Scientific Appoints Dental Industry Veteran Scott Mahnken as New Director of Marketing
6. Skinvisible Appoints New Board Member
7. Tigris Pharmaceuticals Appoints Pedro Granadillo to Board of Directors
8. Neurochem appoints Mr. Gary Schmid as CEO of new nutraceutical business
9. Crdentia Appoints Charlie Mayhone to Director of Operations for its National Travel Division and Charlotte, North Carolina Market
10. National Institutes of Health Appoints Timothy C. Birdsall, ND to CAM Advisory Council
11. CPF Appoints Mishka Michon Chief Executive Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/22/2014)... New Jersey Institute of Technology (NJIT) today to ... launch of the New Jersey Innovation Institute (NJII), ... for business innovation through the leveraging of industry, ... Senator Cory Booker, Panasonic Corp. of North America ... Governor Kim Guadagno, New Jersey Secretary of Higher ...
(Date:4/22/2014)... the last few decades researchers have characterized a set ... and behavior in all types of species, from flies ... identified, but researchers surmise there are more. A team ... of Pennsylvania wondered if big-data approaches could find them. ... by John Hogenesch, PhD, professor of Pharmacology and first ...
(Date:4/22/2014)... 22, 2014 Researchers at UT Southwestern Medical Center ... depression . , A team of physician-scientists ... which ghrelin (a hormone with natural anti-depressant properties) works ... powerful new treatment for depression in the form of ... The study, published online in April,s issue of ...
(Date:4/22/2014)... of pregnancy among women using a newer method of ... times greater over a 10-year period than using the ... at Yale University and UC Davis has found. ... Contraception , the study found the higher risk of ... brand name Essure. , "This study provides essential ...
(Date:4/22/2014)... DC (April 22, 2014) The International Communication ... 22-26 in Seattle, Washington. The theme of the ... means in a networked and digital society. , ... attended by over 2,200 Communication scholars representing over ... scholarly international communication conference in the world. This ...
Breaking Medicine News(10 mins):Health News:Government and industry leaders herald launch of NJIT's New Jersey Innovation Institute 2Health News:Bioinformatics profiling identifies a new mammalian clock gene 2Health News:Depressed? Researchers identify new anti-depressant mechanisms, therapeutic approaches 2Health News:Depressed? Researchers identify new anti-depressant mechanisms, therapeutic approaches 3Health News:Risk of pregnancy greater with newer method of female sterilization 2Health News:Risk of pregnancy greater with newer method of female sterilization 3Health News:International Communication Association to hold Annual Conference in Seattle, Washington 2
... study says, , MONDAY, Nov. 9 (HealthDay News) -- Researchers ... penises by growing new penile tissue in the lab and ... application is a ways off, researchers say the technique could ... men. , "We were able to show the tissue was ...
... ... 2010, Provides First Responders with a Forensic Toolkit , ... Cambridge, MA (Vocus) November 9, 2009 -- When Stefan Schmitt of ... Afghanistan , he realized he would need a team of experts to help interpret the ...
... Ambassador , WHITE PLAINS, N.Y., Nov. 9 Joshua ... many underdeveloped organs that doctors could not say whether he would ... hear. Today, the 6-year-old was named March of Dimes 2010 National ... of motherhood and I was completely devastated. My husband, Lee, and ...
... however , MONDAY, Nov. 9 (HealthDay News) -- After a ... of cancer recurrence in the affected breast, a new study ... increased risk of developing breast cancer, and experts have suspected ... increased risk of cancer recurrence at the site of the ...
... PITTSFIELD, Maine, Nov. 9 At a time when ... concerned about finding affordable health insurance, they now have ... Options® Preferred Provider Organization (PPO) Medicare Advantage plan provides ... a Medicare Supplement plan. People with Medicare can ...
... , Neurologists will use funds to move lab ... pain from nerve damage , ANN ARBOR, Mich., ... of Neurology have received a $1.8 million grant to ... condition in which patients experience pain because of damage ...
Cached Medicine News:Health News:Scientists Grow New Penile Tissue in the Lab 2Health News:Scientists Grow New Penile Tissue in the Lab 3Health News:Physicians for Human Rights Offers Training in Crime Scene Documentation 2Health News:Physicians for Human Rights Offers Training in Crime Scene Documentation 3Health News:Physicians for Human Rights Offers Training in Crime Scene Documentation 4Health News:Six-Year-Old Survivor Fights for Preemies Like Himself 2Health News:Six-Year-Old Survivor Fights for Preemies Like Himself 3Health News:Dense Breasts Raise Risk of Cancer Recurrence 2Health News:Dense Breasts Raise Risk of Cancer Recurrence 3Health News:Maine Residents With Medicare Searching for Affordable and Innovative Insurance Have Competitive Medicare Advantage Option 2Health News:U-M Researchers Receive $1.8 Million Grant to Develop New Therapy for Neuropathic Pain 2
(Date:1/15/2014)... 2014 Tegra Medical is very pleased to announce the ... new Chief Executive Officer.  Mark was promoted from his current ... the company,s four facilities in Massachusetts , ... joined Tegra Medical in 2012 with 20+ years of broad-based ...
(Date:1/15/2014)...  According to Millennium Research Group (MRG), the global ... the United States and European transcatheter ... moderately through 2022, with embolization particles representing one ... in drug-eluting beads (DEBs) and radioembolization spheres in ...
(Date:1/15/2014)... NEW YORK , Jan. 15, 2014 ... research report is available in its catalogue: ... Technologies for Advanced Drug Delivery Systems -- ... http://www.reportlinker.com/p01940411/Global-Markets-and-Technologies-for-Advanced-Drug-Delivery-Systems----Focus-on-End-Users.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_Delivery_Technology STUDY OBJECTIVES ...
Breaking Medicine Technology:Tegra Medical Appoints New Chief Executive Officer 2Tegra Medical Appoints New Chief Executive Officer 3US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18
... , ... 2020; significant funding gaps remain, others must join effort , ... and Melinda Gates announced today that their foundation will commit ... research, develop and deliver vaccines for the world,s poorest countries. ...
... , UNION CITY, Calif. , Jan. 28 ... point-of-care blood analysis systems, today reported financial results for the fiscal quarter ... , Revenues of $31.0 million , up 15% over last ... million , up 9% over last year,s comparable quarter. Veterinary market ...
Cached Medicine Technology:Bill and Melinda Gates Pledge $10 Billion in Call for Decade of Vaccines 2Bill and Melinda Gates Pledge $10 Billion in Call for Decade of Vaccines 3Bill and Melinda Gates Pledge $10 Billion in Call for Decade of Vaccines 4Bill and Melinda Gates Pledge $10 Billion in Call for Decade of Vaccines 5Bill and Melinda Gates Pledge $10 Billion in Call for Decade of Vaccines 6Abaxis Reports Record Revenues for the Third Quarter of Fiscal 2010 2Abaxis Reports Record Revenues for the Third Quarter of Fiscal 2010 3Abaxis Reports Record Revenues for the Third Quarter of Fiscal 2010 4Abaxis Reports Record Revenues for the Third Quarter of Fiscal 2010 5Abaxis Reports Record Revenues for the Third Quarter of Fiscal 2010 6Abaxis Reports Record Revenues for the Third Quarter of Fiscal 2010 7Abaxis Reports Record Revenues for the Third Quarter of Fiscal 2010 8Abaxis Reports Record Revenues for the Third Quarter of Fiscal 2010 9Abaxis Reports Record Revenues for the Third Quarter of Fiscal 2010 10Abaxis Reports Record Revenues for the Third Quarter of Fiscal 2010 11Abaxis Reports Record Revenues for the Third Quarter of Fiscal 2010 12
... A concentrated enzymatic ... and semi-automated hematology instruments. ... on all Abbott CELL-DYN® ... differential instruments. The shelf ...
Streck-Diluent CD is a balanced electrolyte solution manufactured specifically for use as a diluent for blood cell counting and sizing on the Abbott CELL-DYN® 1800....
Streck-Diluent IIIA is a balanced electrolyte solution manufactured specifically for use as a diluent for blood cell counting and sizing on the Abbott CELL-DYN® 1700. The shelf life is one year f...
An environmentally-safe, CN-free lytic reagent designed for use on the Abbott CELL-DYN® 1800 three-part differential hematology analyzer....
Medicine Products: